المؤلفون: E. E. A. P. Mulder, K. de Joode, S. Litière, A. J. ten Tije, K. P. M. Suijkerbuijk, M. J. Boers-Sonderen, G. A. P. Hospers, J. W. B. de Groot, A. J. M. van den Eertwegh, M. J. B. Aarts, D. Piersma, R. S. van Rijn, E. Kapiteijn, G. Vreugdenhil, F. W. P. J. van den Berkmortel, E. Oomen-de Hoop, M. G. Franken, B. Ryll, P. Rutkowski, S. Sleijfer, J. B. A. G. Haanen, A. A. M. van der Veldt

المصدر: BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)

مصطلحات موضوعية: Melanoma, Advanced and metastatic, PD-1 blockade, Response (complete or partial), Health-related quality of life, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1471-2407

URL الوصول: https://doaj.org/article/1258e8cfb799432884b62bfb054d74e9

المؤلفون: Mulder, E. E. A. P.^{Aff1, Aff2}, de Joode, K., Litière, S., ten Tije, A. J., Suijkerbuijk, K. P. M., Boers-Sonderen, M. J., Hospers, G. A. P., de Groot, J. W. B., van den Eertwegh, A. J. M., Aarts, M. J. B., Piersma, D., van Rijn, R. S., Kapiteijn, E., Vreugdenhil, G., van den Berkmortel, F. W. P. J., Hoop, E. Oomen-de, Franken, M. G., Ryll, B., Rutkowski, P., Sleijfer, S., Haanen, J. B. A. G., van der Veldt, A. A. M.^{Aff1, Aff20}

المصدر: BMC Cancer. 21(1)

المؤلفون: K. de Joode, R van Rijn, Ellen Kapiteijn, A.J. ten Tije, Geke A. P. Hospers, Stefan Sleijfer, J.W.B. de Groot, Djura Piersma, Piotr Rutkowski, Karijn P M Suijkerbuijk, Bettina Ryll, J.B.A.G. Haanen, A.A.M. Van der Veldt, Maureen J.B. Aarts, Marye J Boers-Sonderen, Evalyn E. A. P. Mulder, G. Vreugdenhil, Saskia Litière, E. Oomen-de Hoop, F.W.P.J. van den Berkmortel, A.J.M. van den Eertwegh, M Franken

المساهمون: Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Surgery, Medical Oncology, Hematology, Health Technology Assessment (HTA), Radiology & Nuclear Medicine

المصدر: BMC Cancer, 21(1):323. BioMed Central Ltd
BMC Cancer, 21(1):323. BMC
BMC Cancer, 21
BMC Cancer, 21(1). BMC
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer, 21(1):323. BioMed Central Ltd.
BMC Cancer, 21, 1

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Consensus, Skin Neoplasms, Time Factors, Health-related quality of life, Programmed Cell Death 1 Receptor, PD-1 blockade, Pembrolizumab, lcsh:RC254-282, Drug Administration Schedule, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Study Protocol, 03 medical and health sciences, 0302 clinical medicine, Advanced and metastatic, Quality of life, SDG 3 - Good Health and Well-being, Surgical oncology, Internal medicine, Genetics, Humans, Multicenter Studies as Topic, Medicine, Prospective Studies, 030212 general & internal medicine, Adverse effect, Immune Checkpoint Inhibitors, Melanoma, Response Evaluation Criteria in Solid Tumors, business.industry, Standard of Care, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, medicine.disease, Blockade, Discontinuation, Response (complete or partial), Withholding Treatment, Oncology, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, Quality of Life, Female, Nivolumab, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3acffd460aa0855610702882d7e64537
https://doi.org/10.1186/s12885-021-08018-w

مصطلحات موضوعية: Advanced and metastatic, Health-related quality of life, PD-1 blockade, Melanoma, Response (complete or partial)

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_______202::d23b72c2081be5d3346903d52ba7adc3